Close Menu

diabetic nephropathy

Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The effort aims to identify a suite of markers that could aid in management of type II diabetes and related conditions like retinopathy and kidney damage.

Named PromarkerD, the test is intended to predict risk of developing kidney disease in diabetics and diagnose patients with diabetic kidney disease.

Proteomics firm Proteomics International said this week that it has received a A$1 million (US$ 1 million) grant from Commercialisation Australia – an initiative of the Australian government – to develop its protein biomarkers for diabetic nephropathy into a companion diagnostic.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – EMD Millipore and Proteomic International have signed a collaborative agreement to validate biomarkers related to diabetic nephropathy, the firms said today.

The company presented a panel of 13 biomarkers for the disease at last month's Human Proteome Organization annual meeting and is looking for partners and funding to develop it as a commercial diagnostic.

The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.

There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.

The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.

In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.